Key clinical point: Adding isatuximab to pomalidomide and dexamethasone can prolong progression-free survival in patients with relapsed/refractory multiple myeloma.

Major finding: The median progression-free survival was 11.53 months in patients who received isatuximab plus pomalidomide and dexamethasone, compared with 6.47 months in patients who received only pomalidomide and dexamethasone (hazard ratio, 0.596; P = .001).

Study details: A phase 3 trial of 307 patients with relapsed/refractory multiple myeloma.

Disclosures: The trial was funded by Sanofi. The speaker reported relationships with Celgene, Janssen, and Takeda. His coinvestigators reported relationships with a range of companies.